Cancer Research Aziza Shad  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 6271, August 1, 2008. doi: 10.1158/0008-5472.CAN-07-6769
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Opel, D.
Right arrow Articles by Fulda, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Opel, D.
Right arrow Articles by Fulda, S.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor– and Drug-Induced Apoptosis

Daniela Opel1, Mike-Andrew Westhoff1, Ariane Bender1, Veit Braun2, Klaus-Michael Debatin1 and Simone Fulda1

1 University Children's Hospital, Ulm, Germany and 2 Department of Neurosurgery, Evangelisches Jung-Stilling-Krankenhaus, Siegen, Germany

Requests for reprints: Simone Fulda, University Children's Hospital, Eythstrasse 24, D-89075 Ulm, Germany. Phone: 49-731-5005-7034; Fax: 49-731-5005-7042; E-mail: simone.fulda{at}uniklinik-ulm.de.

Key Words: apoptosis • PI3K • glioblastoma • TRAIL • chemotherapy

The aberrant activity of the phosphatidylinositol 3-kinase (PI3K) pathway has been reported to correlate with adverse clinical outcome in human glioblastoma in vivo. However, the question of how this survival network can be successfully targeted to restore the sensitivity of glioblastoma to apoptosis induction has not yet been answered. Here, we report that inhibition of PI3K by LY294002 broadly sensitizes wild-type and mutant PTEN glioblastoma cells to both death receptor– and chemotherapy-induced apoptosis, whereas mammalian target of rapamycin (mTOR) inhibition is not sufficient to restore apoptosis sensitivity. LY294002 significantly enhances apoptosis triggered by tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), agonistic anti-CD95 antibodies, or several anticancer drugs (i.e., doxorubicin, etoposide, and vincristine) in a highly synergistic manner. In addition, LY294002 cooperates with TRAIL or doxorubicin to suppress colony formation, thus also showing a strong effect on long-term survival. Similarly, genetic knockdown of PI3K subunits p110{alpha} and/or p110β by RNA interference (RNAi) primes glioblastoma cells for TRAIL- or doxorubicin-mediated apoptosis. In contrast to PI3K inhibition, pharmacologic or genetic blockade of mTOR by RAD001 (everolimus), rapamycin, or RNAi fails to enhance TRAIL- or doxorubicin-induced apoptosis. Analysis of apoptosis pathways reveals that PI3K inhibition acts in concert with TRAIL or doxorubicin to trigger mitochondrial membrane permeabilization, caspase activation, and caspase-dependent apoptosis, which are abolished by the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. Most importantly, PI3K inhibition by LY294002 sensitizes primary cultured glioblastoma cells obtained from surgical specimens to TRAIL- or chemotherapy-induced cell death. By showing that PI3K inhibition broadly primes glioblastoma cells for apoptosis, our findings provide the rationale for using PI3K inhibitors in combination regimens to enhance TRAIL- or chemotherapy-induced apoptosis in glioblastoma. [Cancer Res 2008;68(15):6271–80]




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system
Mol. Cancer Ther., November 1, 2009; 8(11): 3140 - 3150.



Home page
Clin. Cancer Res.Home page
W. Hartmann, J. Kuchler, A. Koch, N. Friedrichs, A. Waha, E. Endl, J. Czerwitzki, D. Metzger, S. Steiner, P. Wurst, et al.
Activation of Phosphatidylinositol-3'-kinase/AKT Signaling Is Essential in Hepatoblastoma Survival
Clin. Cancer Res., July 15, 2009; 15(14): 4538 - 4545.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
Brain, June 1, 2009; 132(6): 1509 - 1522.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Giussani, L. Brioschi, R. Bassi, L. Riboni, and P. Viani
Phosphatidylinositol 3-Kinase/AKT Pathway Regulates the Endoplasmic Reticulum to Golgi Traffic of Ceramide in Glioma Cells: A LINK BETWEEN LIPID SIGNALING PATHWAYS INVOLVED IN THE CONTROL OF CELL SURVIVAL
J. Biol. Chem., February 20, 2009; 284(8): 5088 - 5096.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Riad, S. Bien, D. Westermann, P. M. Becher, K. Loya, U. Landmesser, H. K. Kroemer, H. P. Schultheiss, and C. Tschope
Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice
Cancer Res., January 15, 2009; 69(2): 695 - 699.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.